MX2012001061A - Hidrogeles biodegradables insolubles en agua a base de polietilenglicol. - Google Patents
Hidrogeles biodegradables insolubles en agua a base de polietilenglicol.Info
- Publication number
- MX2012001061A MX2012001061A MX2012001061A MX2012001061A MX2012001061A MX 2012001061 A MX2012001061 A MX 2012001061A MX 2012001061 A MX2012001061 A MX 2012001061A MX 2012001061 A MX2012001061 A MX 2012001061A MX 2012001061 A MX2012001061 A MX 2012001061A
- Authority
- MX
- Mexico
- Prior art keywords
- water
- backbone moieties
- polyethylene glycol
- hydrogel
- hydrogels
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Polyethers (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Colloid Chemistry (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
Abstract
La presente invención se refiere a hidrogeles insolubles en agua a base de polietilenglicol biodegradables que comprende porciones de armazón principal que están interconectadas por enlaces hidrolíticamente degradables, las porciones de armazón principal comprenden además grupos funcionales reactivos, en donde el hidrogel insoluble en agua se caracteriza además porque la relación entre el periodo de tiempo para la degradación completa del hidrogel por hidrólisis de los enlaces degradables en productos de degradación hidrosolubles que comprenden una o más porciones de armazón principal y el periodo de tiempo para liberación de los primeros 10% molares de productos de degradación hidrosolubles que comprenden una o más porciones de armazón principal con base en la cantidad total de porciones de armazón principal en el hidrogel es mayor que 1 e igual a o menor que 2. La invención se refiere además a conjugados de estos hidrogeles con ligandos o grupos de ligación, profármacos y composiciones farmacéuticas, así como a su uso en un medicamento.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09167026 | 2009-07-31 | ||
EP09172339 | 2009-10-06 | ||
PCT/EP2010/061155 WO2011012715A1 (en) | 2009-07-31 | 2010-07-30 | Biodegradable polyethylene glycol based water-insoluble hydrogels |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012001061A true MX2012001061A (es) | 2012-03-26 |
MX343925B MX343925B (es) | 2016-11-29 |
Family
ID=43027631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012001061A MX343925B (es) | 2009-07-31 | 2010-07-30 | Hidrogeles biodegradables insolubles en agua a base de polietilenglicol. |
Country Status (23)
Country | Link |
---|---|
US (1) | US11559482B2 (es) |
EP (2) | EP2459220B1 (es) |
JP (1) | JP5904941B2 (es) |
KR (1) | KR101770844B1 (es) |
CN (1) | CN102573913B (es) |
AU (1) | AU2010277556B2 (es) |
BR (1) | BR112012002280B1 (es) |
CA (1) | CA2769162C (es) |
ES (1) | ES2833035T3 (es) |
HK (1) | HK1173082A1 (es) |
HR (1) | HRP20201609T1 (es) |
HU (1) | HUE052816T2 (es) |
IL (1) | IL217743A (es) |
LT (1) | LT2459220T (es) |
MX (1) | MX343925B (es) |
MY (1) | MY156872A (es) |
NZ (1) | NZ597960A (es) |
PL (1) | PL2459220T3 (es) |
RU (1) | RU2554854C9 (es) |
SG (1) | SG177761A1 (es) |
SI (1) | SI2459220T1 (es) |
WO (1) | WO2011012715A1 (es) |
ZA (1) | ZA201200686B (es) |
Families Citing this family (146)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120089843A (ko) | 2009-07-31 | 2012-08-14 | 사노피-아벤티스 도이칠란트 게엠베하 | 인슐린 링커 접합체를 포함한 프로드럭 |
MX2012001141A (es) | 2009-07-31 | 2012-03-29 | Sanofi Aventis Deutschland | Composicion de insulina de accion prolongada. |
MY157640A (en) | 2009-10-29 | 2016-07-15 | Ascendis Pharma As | Sterilization of biodegradable hydrogels |
SI2512450T1 (en) | 2009-12-15 | 2018-05-31 | Ascendis Pharma Endocrinology Division A/S | A dry growth hormone composition transiently bound to a polymeric carrier |
EP2525831B1 (en) | 2010-01-22 | 2019-05-15 | Ascendis Pharma A/S | Carrier-linked carbamate prodrug linkers |
EP2525829A1 (en) | 2010-01-22 | 2012-11-28 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
US9062094B2 (en) | 2010-01-22 | 2015-06-23 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
AU2011289579B2 (en) | 2010-08-10 | 2016-11-17 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
EP2438930A1 (en) | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Prodrugs comprising an exendin linker conjugate |
US10451897B2 (en) | 2011-03-18 | 2019-10-22 | Johnson & Johnson Vision Care, Inc. | Components with multiple energization elements for biomedical devices |
US20120283325A1 (en) * | 2011-05-03 | 2012-11-08 | Telik, Inc. | Excipient compatibility with ezatiostat |
JP6302835B2 (ja) * | 2011-06-21 | 2018-03-28 | ビーブイダブリュ ホールディング エージー | ボスウェル酸を含む医療デバイス |
CN103857413A (zh) * | 2011-08-12 | 2014-06-11 | 阿森迪斯药物股份有限公司 | 载体连接的曲罗尼尔前药 |
WO2013024053A1 (en) | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | Carrier-linked prodrugs having reversible carboxylic ester linkages |
KR20140082649A (ko) | 2011-08-12 | 2014-07-02 | 아센디스 파마 에이에스 | 프로스타사이클린의 서방형 조성물 |
WO2013053856A1 (en) * | 2011-10-12 | 2013-04-18 | Ascendis Pharma A/S | Prevention and treatment of ocular conditions |
IN2014DN03213A (es) * | 2011-11-03 | 2015-05-22 | Bayer Ip Gmbh | |
US8857983B2 (en) | 2012-01-26 | 2014-10-14 | Johnson & Johnson Vision Care, Inc. | Ophthalmic lens assembly having an integrated antenna structure |
CA2868925C (en) | 2012-04-25 | 2020-01-21 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
US20140073589A1 (en) * | 2012-06-27 | 2014-03-13 | Shire Ag | Amphetamine Prodrugs |
EP2888234B1 (en) | 2012-08-21 | 2017-12-06 | Janssen Pharmaceutica NV | Haptens of aripiprazole and their use in immunoassays |
AU2013305879B2 (en) | 2012-08-21 | 2017-10-12 | Saladax Biomedical Inc. | Antibodies to aripiprazole and use thereof |
JP6389176B2 (ja) | 2012-08-21 | 2018-09-12 | ヤンセン ファーマシューティカ エヌ.ベー. | アリピプラゾールハプテンに対する抗体及びその使用 |
EP2888287A4 (en) | 2012-08-21 | 2016-04-20 | Ortho Clinical Diagnostics Inc | ANTIBODIES AGAINST PALIPERIDONE HAPTENES AND THEIR USE |
AU2013305965B2 (en) | 2012-08-21 | 2017-08-24 | Saladax Biomedical Inc. | Antibodies to paliperidone and use thereof |
WO2014031645A1 (en) | 2012-08-21 | 2014-02-27 | Ortho-Clinical Diagnostics, Inc | Antibodies to risperidone haptens and use thereof |
EP3556759B1 (en) * | 2012-08-21 | 2023-11-29 | Janssen Pharmaceutica NV | Haptens of paliperidone |
US9664700B2 (en) | 2012-08-21 | 2017-05-30 | Janssen Pharmaceutica Nv | Antibodies to risperidone and use thereof |
SG11201501920PA (en) * | 2012-10-11 | 2015-04-29 | Ascendis Pharma As | Diagnosis, prevention and treatment of diseases of the joint |
MY177912A (en) | 2012-10-11 | 2020-09-25 | Ascendis Pharma Ophthalmology Div A/S | Vegf neutralizing prodrugs for the treatment of ocular conditions |
EP2906617B1 (en) * | 2012-10-11 | 2018-03-14 | Ascendis Pharma A/S | Hydrogel prodrugs |
AU2013353985B2 (en) | 2012-12-07 | 2017-07-13 | Ascendis Pharma A/S | Carrier-linked prostanoid prodrugs |
US20140271885A1 (en) * | 2013-03-15 | 2014-09-18 | Intezyne Technologies, Inc. | Copolymers for stable micelle formulations |
CA2907830C (en) | 2013-04-22 | 2022-03-29 | Ascendis Pharma A/S | Hydrogel-linked prodrugs releasing tagged drugs |
JP6311008B2 (ja) * | 2013-04-22 | 2018-04-11 | アセンディス ファーマ エー/エス | 修飾されたヒドロゲル |
US10130711B2 (en) | 2013-06-19 | 2018-11-20 | The Regents Of The University Of California | Chemical structures for localized delivery of therapeutic agents |
RU2543375C1 (ru) * | 2013-07-29 | 2015-02-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный университет" | Комплексное соединение производного метилурацила с органической кислотой и способ его получения |
JP6539274B2 (ja) | 2013-08-12 | 2019-07-03 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | 押出成形された即放性乱用抑止性丸剤 |
ES2721098T3 (es) | 2013-10-01 | 2019-07-26 | Glaxosmithkline Ip Dev Ltd | Compuestos para cromatografía de afinidad |
EP3054982B1 (en) * | 2013-10-08 | 2019-05-01 | Ascendis Pharma A/S | Hydrogel-linked il-1ra prodrug |
CN103554296B (zh) * | 2013-10-12 | 2015-09-16 | 天津大学 | 一种亚油酸改性葡聚糖及制备高分子脂质体的方法 |
CA2929201A1 (en) | 2013-11-11 | 2015-05-14 | Ascendis Pharma Relaxin Division A/S | Relaxin prodrugs |
US9675607B2 (en) * | 2013-11-13 | 2017-06-13 | Northwestern University | Epimorphic regeneration and related hydrogel delivery systems |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
CN103706233A (zh) * | 2013-12-17 | 2014-04-09 | 杨亮月 | 一种环氧乙烷零排放处理体系及方法 |
US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
KR20160135214A (ko) | 2014-02-21 | 2016-11-25 | 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) | 글리코타겟팅 치료제 |
AU2015229014B2 (en) | 2014-03-14 | 2019-07-25 | The Regents Of The University Of California | TCO conjugates and methods for delivery of therapeutic agents |
JP6651500B2 (ja) | 2014-07-17 | 2020-02-19 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 生物医学的応用のための制御可能な自己アニーリング型ミクロゲル粒子 |
JP6371463B2 (ja) | 2014-07-17 | 2018-08-08 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | 即時放出性乱用抑止性液体充填剤形 |
AU2015299055C1 (en) | 2014-08-06 | 2021-05-06 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
US9793536B2 (en) | 2014-08-21 | 2017-10-17 | Johnson & Johnson Vision Care, Inc. | Pellet form cathode for use in a biocompatible battery |
US9715130B2 (en) | 2014-08-21 | 2017-07-25 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus to form separators for biocompatible energization elements for biomedical devices |
US9941547B2 (en) | 2014-08-21 | 2018-04-10 | Johnson & Johnson Vision Care, Inc. | Biomedical energization elements with polymer electrolytes and cavity structures |
US9923177B2 (en) * | 2014-08-21 | 2018-03-20 | Johnson & Johnson Vision Care, Inc. | Biocompatibility of biomedical energization elements |
US10627651B2 (en) | 2014-08-21 | 2020-04-21 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus to form biocompatible energization primary elements for biomedical devices with electroless sealing layers |
US10361405B2 (en) | 2014-08-21 | 2019-07-23 | Johnson & Johnson Vision Care, Inc. | Biomedical energization elements with polymer electrolytes |
US10381687B2 (en) | 2014-08-21 | 2019-08-13 | Johnson & Johnson Vision Care, Inc. | Methods of forming biocompatible rechargable energization elements for biomedical devices |
US9599842B2 (en) | 2014-08-21 | 2017-03-21 | Johnson & Johnson Vision Care, Inc. | Device and methods for sealing and encapsulation for biocompatible energization elements |
US9383593B2 (en) | 2014-08-21 | 2016-07-05 | Johnson & Johnson Vision Care, Inc. | Methods to form biocompatible energization elements for biomedical devices comprising laminates and placed separators |
US10361404B2 (en) | 2014-08-21 | 2019-07-23 | Johnson & Johnson Vision Care, Inc. | Anodes for use in biocompatible energization elements |
AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
WO2016063959A1 (ja) | 2014-10-24 | 2016-04-28 | 日油株式会社 | 環状ベンジリデンアセタールリンカーを有する抗体―薬物複合体 |
WO2016196124A2 (en) | 2015-05-29 | 2016-12-08 | Ascendis Pharma Inc. | Prodrugs comprising a pyroglutamate linker |
CN108137681A (zh) | 2015-09-23 | 2018-06-08 | 豪夫迈·罗氏有限公司 | 抗-vegf抗体的优化的变体 |
US11458041B2 (en) * | 2015-10-08 | 2022-10-04 | Ocular Therapeutix, Inc. | Punctal plug and bioadhesives |
US20170136144A1 (en) | 2015-11-12 | 2017-05-18 | John C. Herr | Compositions and methods for vas-occlusive contraception |
EP3390449A1 (en) | 2015-12-17 | 2018-10-24 | Janssen Pharmaceutica N.V. | Antibodies to risperidone and use thereof |
WO2017101883A1 (zh) * | 2015-12-18 | 2017-06-22 | 韩捷 | 一种可在生理条件下降解的水凝胶 |
CA3009317A1 (en) | 2015-12-23 | 2017-06-29 | Viking Scientific, Inc. | Hydrogel prodrug for treatment |
US11931480B2 (en) | 2016-02-16 | 2024-03-19 | The Regents Of The University Of California | Microporous annealed particle gels and methods of use |
US10345620B2 (en) | 2016-02-18 | 2019-07-09 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus to form biocompatible energization elements incorporating fuel cells for biomedical devices |
MA45809A (fr) | 2016-03-01 | 2019-01-09 | Ascendis Pharma Bone Diseases As | Promédicaments de pth |
EP3439670A4 (en) | 2016-04-08 | 2019-11-27 | The Regents of the University of California | MODIFIED HYALURONIC ACID HYGELS AND PROTEINS FOR THE TEMPORARY RELEASE OF BIOLOGICAL ACTIVE SUBSTANCES |
CN105963792B (zh) * | 2016-04-29 | 2019-03-22 | 深圳迈普再生医学科技有限公司 | 医用水凝胶组合物,医用水凝胶及其制备方法与应用 |
WO2018011266A1 (en) | 2016-07-13 | 2018-01-18 | Ascendis Pharma A/S | Conjugation method for carrier-linked prodrugs |
SI3518930T1 (sl) | 2016-09-29 | 2023-06-30 | Ascendis Pharma Growth Disorders A/S | Kombinirana terapija z agonisti CNP s kontroliranim sproščanjem |
BR112019005533A2 (pt) | 2016-09-29 | 2019-06-18 | Ascendis Pharma Bone Diseases As | regime de dosagem para um composto de pth de liberação controlada |
WO2018060311A1 (en) | 2016-09-29 | 2018-04-05 | Ascendis Pharma Bone Diseases A/S | Incremental dose finding in controlled-release pth compounds |
ES2943720T3 (es) | 2016-09-29 | 2023-06-15 | Ascendis Pharma Bone Diseases As | Compuestos de PTH con bajas relaciones de pico a valle |
EP3562523A4 (en) | 2016-12-29 | 2020-09-30 | Tempo Therapeutics, Inc. | PROCESSES AND SYSTEMS FOR THE TREATMENT OF A MEDICAL IMPLANT SITE |
LT3592392T (lt) | 2017-03-10 | 2024-01-25 | University Of Louisville Research Foundation, Inc. | Fasl modifikuotos biomedžiagos su imunomoduliacine funkcija |
IL269506B2 (en) | 2017-03-22 | 2024-04-01 | Genentech Inc | Hyaluronic acid cross-linked hydrogel preparations and methods |
JOP20190245A1 (ar) * | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
CN108864258A (zh) * | 2017-05-12 | 2018-11-23 | 北京康明海慧生物科技有限公司 | 具有抑制肿瘤功能的peg化多肽及其制备方法与应用 |
EP3638296A1 (en) | 2017-06-16 | 2020-04-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
CN107583104B (zh) * | 2017-10-31 | 2020-12-01 | 无锡中科光远生物材料有限公司 | 一种可注射的用于脊柱修复的凝胶材料 |
AU2018360406A1 (en) * | 2017-11-02 | 2020-05-21 | Tarsier Pharma Ltd | Phosphorylcholine-tuftsin conjugate for treating ocular inflammation |
CN107880288A (zh) * | 2017-11-29 | 2018-04-06 | 桂林华诺威生物科技有限公司 | 一种透明质酸钠凝胶的制备方法 |
CN108096630B (zh) * | 2018-01-29 | 2020-09-04 | 暨南大学 | 一种载淫羊藿苷和去铁胺的聚乳酸基骨组织支架及制备方法和应用 |
MA52662A (fr) | 2018-03-28 | 2021-02-17 | Ascendis Pharma Oncology Div A/S | Conjugués d'il-2 |
FR3079421A1 (fr) * | 2018-03-28 | 2019-10-04 | Edix Sa | Presentations injectables, seringues et compositions a liberation prolongee et/ou controlee de lanreotide |
CN110865130B (zh) * | 2018-08-27 | 2023-08-22 | 北京海晶生物医药科技有限公司 | 一种盐酸奥洛他定及其有关物质的检测方法 |
WO2020064846A1 (en) | 2018-09-26 | 2020-04-02 | Ascendis Pharma A/S | Novel hydrogel conjugates |
AR116566A1 (es) | 2018-10-03 | 2021-05-19 | Novartis Ag | Administración sostenida de polipéptidos similares a la angiopoyetina 3 |
CN111077235B (zh) * | 2018-10-19 | 2023-09-08 | 重庆医药工业研究院有限责任公司 | 一种测定2-[(2-甲基-5-溴苯基)甲基]-5-(4-氟苯基)噻吩杂质的方法 |
AU2020204786A1 (en) | 2019-01-04 | 2021-06-10 | Ascendis Pharma Oncology Division A/S | Induction of sustained local inflammation |
AU2020205029A1 (en) | 2019-01-04 | 2021-06-24 | Ascendis Pharma Oncology Division A/S | Minimization of systemic inflammation |
CA3125479A1 (en) | 2019-01-04 | 2020-07-09 | Ascendis Pharma Oncology Division A/S | Sustained local drug levels for innate immune agonists |
CN113557033A (zh) * | 2019-01-04 | 2021-10-26 | 阿森迪斯药物肿瘤股份有限公司 | 模式识别受体激动剂的缀合物 |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
AU2020288650A1 (en) * | 2019-06-07 | 2021-12-09 | Likarda, LLC | Tunable degradation in hydrogel microparticles |
WO2020254617A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Anti-ctla4 compounds with localized pk properties |
CA3143442A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma A/S | Conjugates of heteroaromatic nitrogen-comprising compounds |
WO2020254607A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Anti-ctla4 compounds with localized pd properties |
WO2020254612A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Controlled-release tyrosine kinase inhibitor compounds with localized pd properties |
WO2020254602A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma A/S | Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds |
WO2020254613A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Controlled-release tyrosine kinase inhibitor compounds with localized pk properties |
US20230102309A1 (en) | 2019-06-21 | 2023-03-30 | Ascendis Pharma Oncology Division A/S | Tyrosine kinase inhibitor conjugates |
EP3986479A1 (en) | 2019-06-21 | 2022-04-27 | Ascendis Pharma Oncology Division A/S | Anti-ctla4 conjugates |
EP3986477A1 (en) | 2019-06-21 | 2022-04-27 | Ascendis Pharma A/S | CONJUGATES OF pi-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS |
PE20220902A1 (es) * | 2019-06-26 | 2022-05-30 | Biorchestra Co Ltd | Nanoparticulas micelares y sus usos |
US20230133656A1 (en) * | 2019-07-03 | 2023-05-04 | Molly Sandra Shoichet | Hydrogel compositions and uses thereof |
CN112168820B (zh) * | 2019-07-05 | 2023-09-29 | 中国科学院生物物理研究所 | SRCAP ATPase抑制剂在结直肠癌治疗中的应用 |
CN114449998A (zh) * | 2019-08-29 | 2022-05-06 | 保罗·道格拉斯·戈德弗林 | 口服递送剂型水凝胶、其制备方法和使用方法 |
BR112022009568A2 (pt) * | 2019-11-19 | 2022-08-02 | Lubrizol Advanced Mat Inc | Composição de poliuretano, e, revestimento |
US20230110994A1 (en) | 2020-01-03 | 2023-04-13 | Ascendis Pharma A/S | Conjugates undergoing intramolecular rearrangements |
CN111138293B (zh) * | 2020-01-10 | 2023-07-07 | 蚌埠丰原医药科技发展有限公司 | 一种用微通道反应器合成富马酸伊布利特中间体的方法 |
EP3861985B1 (en) | 2020-02-06 | 2023-06-14 | Ocular Therapeutix, Inc. | Compositions and methods for treating ocular diseases |
KR102375663B1 (ko) * | 2020-03-24 | 2022-03-16 | 재단법인대구경북과학기술원 | 무손실 세포 염색 방법 및 장치 |
JP7378638B2 (ja) | 2020-03-25 | 2023-11-13 | オキュラ セラピューティクス,インコーポレイテッド | チロシンキナーゼ阻害剤を含む眼内インプラント |
AU2021269007A1 (en) | 2020-05-04 | 2022-11-24 | Ascendis Pharma A/S | Hydrogel irradiation |
CN113694261B (zh) * | 2020-05-21 | 2022-09-09 | 江苏百赛飞生物科技有限公司 | 一种抗菌复合涂层及其制备方法和制品 |
US20210369651A1 (en) * | 2020-05-28 | 2021-12-02 | Sollievo Pharmaceuticals, Inc | Parenteral delivery of avizafone |
CN116133676A (zh) | 2020-06-03 | 2023-05-16 | 阿森迪斯药物肿瘤股份有限公司 | Il-2序列及其用途 |
US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
EP4192508A1 (en) | 2020-08-05 | 2023-06-14 | Ascendis Pharma A/S | Conjugates comprising reversible linkers and uses thereof |
KR20230057447A (ko) | 2020-08-28 | 2023-04-28 | 아센디스 파마 온콜로지 디비전 에이/에스 | 글리코실화된 il-2 단백질 및 이의 용도 |
AU2021349316A1 (en) | 2020-09-28 | 2023-04-27 | Ascendis Pharma Bone Diseases A/S | Improvement of physical and mental well-being of patients with hypoparathyroidism |
CN112316156B (zh) * | 2020-10-27 | 2022-03-15 | 四川大学 | 具抗氧化和抗菌性的胶原蛋白修复膜、其制备方法及应用 |
KR102437315B1 (ko) * | 2020-11-02 | 2022-08-30 | 아주대학교산학협력단 | 하이브리드 하이드로겔 및 이의 생의학적 용도 |
EP4314035A1 (en) | 2021-04-01 | 2024-02-07 | Ascendis Pharma A/S | Use of long-acting growth hormone for treating inflammation-induced diseases |
CN113304139B (zh) * | 2021-06-30 | 2022-04-29 | 贵州医科大学 | Viniferifuran在制备黄嘌呤氧化酶抑制药物中的应用 |
CN113398145B (zh) * | 2021-07-02 | 2022-10-14 | 合肥康诺生物制药有限公司 | 含nad与氨氯地平的药物组合物及其用途 |
CN113461979A (zh) * | 2021-07-19 | 2021-10-01 | 吉林大学 | 一种通过血红蛋白催化交联的仿贻贝类水凝胶的制备方法 |
WO2023110727A2 (en) | 2021-12-13 | 2023-06-22 | Ascendis Pharma Oncology Division A/S | Novel cancer treatments with tlr7/8 agonists |
CN114469926B (zh) * | 2022-01-28 | 2023-06-27 | 吉林省健维天然生物科技有限公司 | 二氢槲皮素的新用途及二氢槲皮素水凝胶的制备方法 |
CN115109275B (zh) * | 2022-08-29 | 2022-11-01 | 杭州艾名医学科技有限公司 | 一种动态交联可降解水凝胶、制备方法及应用 |
CN115444840B (zh) * | 2022-09-15 | 2023-08-25 | 四川大学 | 一种前药、两性离子水凝胶及其制备方法、应用 |
CN115322397B (zh) * | 2022-09-23 | 2024-04-30 | 福州大学 | 一种预防术后腹腔粘连的两性离子水凝胶及其制备方法 |
CN115537017B (zh) * | 2022-09-27 | 2023-09-01 | 四川大学 | 一种水凝胶及其制备方法和应用 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ249770A (en) | 1992-02-28 | 1996-09-25 | Univ Texas | Biodegradable, polymerisable, substantially water soluble macromer comprising at least one water soluble region, at least one degradable region and at least two free radical polymerisable regions separated by at least one degradable region |
US20020064546A1 (en) * | 1996-09-13 | 2002-05-30 | J. Milton Harris | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
UA72189C2 (uk) * | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
US6348558B1 (en) | 1999-12-10 | 2002-02-19 | Shearwater Corporation | Hydrolytically degradable polymers and hydrogels made therefrom |
US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
US20050260259A1 (en) * | 2004-04-23 | 2005-11-24 | Bolotin Elijah M | Compositions for treatment with glucagon-like peptide, and methods of making and using the same |
WO2003084926A2 (en) | 2002-04-04 | 2003-10-16 | Enzon, Inc. | Polymeric acyl derivatives of indoles |
ATE531447T1 (de) * | 2003-01-17 | 2011-11-15 | Cornell Res Foundation Inc | Injizierbare hydrogel-microsphären aus wässrigem zwei-phasen-system |
JP4698579B2 (ja) | 2003-04-08 | 2011-06-08 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 可逆的peg化薬物 |
WO2005000360A2 (en) | 2003-05-23 | 2005-01-06 | Nektar Therapeutics Al, Corporation | Peg derivatives having an amidocarbonate linkage |
EP2087910B1 (en) * | 2004-03-23 | 2022-05-04 | Ascendis Pharma GmbH | Polymeric prodrugs |
US7968085B2 (en) * | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
DE102004051715A1 (de) | 2004-10-23 | 2005-06-30 | Clariant Gmbh | Flüssigwaschmittel enthaltend Farbfixiermittel |
KR100665672B1 (ko) * | 2005-04-13 | 2007-01-09 | 성균관대학교산학협력단 | 새로운 온도 및 pH 민감성 블록 공중합체 및 이를 이용한고분자 하이드로겔 |
GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
JP2009523494A (ja) | 2006-01-12 | 2009-06-25 | ヒストジェニックス コーポレイション | 破壊された靱帯又は腱の修復及び再構築のための、及び靱帯及び腱の損傷の処置のための方法 |
KR20090055623A (ko) | 2006-09-15 | 2009-06-02 | 엔존 파마슈티컬즈, 인코포레이티드 | 올리고뉴클레오티드 전달을 위한 방해된 에스테르 기재 생분해성 링커 |
GB0619175D0 (en) * | 2006-09-29 | 2006-11-08 | Univ Nottingham | Polymer |
CN101541857B (zh) | 2006-11-27 | 2012-12-12 | 阿克塔马克斯手术器材有限责任公司 | 多官能聚环氧烷、水凝胶和组织粘合剂 |
JP2010519183A (ja) * | 2007-02-06 | 2010-06-03 | インセプト エルエルシー | 生理溶液の溶出のためのタンパク質の沈殿を用いる重合 |
US20080220047A1 (en) * | 2007-03-05 | 2008-09-11 | Sawhney Amarpreet S | Low-swelling biocompatible hydrogels |
CA2685807C (en) | 2007-04-13 | 2016-04-12 | Kuros Biosurgery Ag | Polymeric tissue sealant |
PL2237799T3 (pl) | 2008-02-01 | 2019-09-30 | Ascendis Pharma A/S | Prolek zawierający samorozszczepiający się łącznik |
ES2563061T3 (es) * | 2008-04-28 | 2016-03-10 | Zogenix, Inc. | Nuevas formulaciones para el tratamiento de la migraña |
MY157640A (en) * | 2009-10-29 | 2016-07-15 | Ascendis Pharma As | Sterilization of biodegradable hydrogels |
EP2438930A1 (en) * | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Prodrugs comprising an exendin linker conjugate |
-
2010
- 2010-07-30 MX MX2012001061A patent/MX343925B/es active IP Right Grant
- 2010-07-30 LT LTEP10737075.1T patent/LT2459220T/lt unknown
- 2010-07-30 MY MYPI2012000327A patent/MY156872A/en unknown
- 2010-07-30 AU AU2010277556A patent/AU2010277556B2/en active Active
- 2010-07-30 SG SG2012005625A patent/SG177761A1/en unknown
- 2010-07-30 KR KR1020127005277A patent/KR101770844B1/ko active IP Right Grant
- 2010-07-30 CN CN201080043886.8A patent/CN102573913B/zh active Active
- 2010-07-30 BR BR112012002280A patent/BR112012002280B1/pt active IP Right Grant
- 2010-07-30 EP EP10737075.1A patent/EP2459220B1/en active Active
- 2010-07-30 HU HUE10737075A patent/HUE052816T2/hu unknown
- 2010-07-30 ES ES10737075T patent/ES2833035T3/es active Active
- 2010-07-30 SI SI201032040T patent/SI2459220T1/sl unknown
- 2010-07-30 PL PL10737075T patent/PL2459220T3/pl unknown
- 2010-07-30 EP EP20194835.3A patent/EP3782649A1/en active Pending
- 2010-07-30 JP JP2012522186A patent/JP5904941B2/ja active Active
- 2010-07-30 CA CA2769162A patent/CA2769162C/en active Active
- 2010-07-30 WO PCT/EP2010/061155 patent/WO2011012715A1/en active Application Filing
- 2010-07-30 US US13/387,971 patent/US11559482B2/en active Active
- 2010-07-30 NZ NZ597960A patent/NZ597960A/xx unknown
- 2010-07-30 RU RU2012107137A patent/RU2554854C9/ru active
-
2012
- 2012-01-26 IL IL217743A patent/IL217743A/en active IP Right Grant
- 2012-01-27 ZA ZA2012/00686A patent/ZA201200686B/en unknown
-
2013
- 2013-01-10 HK HK13100394.7A patent/HK1173082A1/xx unknown
-
2020
- 2020-10-07 HR HRP20201609TT patent/HRP20201609T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012001061A (es) | Hidrogeles biodegradables insolubles en agua a base de polietilenglicol. | |
WO2011062965A3 (en) | Targeting monomers and polymers having targeting blocks | |
NZ592139A (en) | Biodegradable polymer - bioactive moiety conjugates | |
WO2011112482A3 (en) | Polymeric drug delivery conjugates and methods of making and using thereof | |
WO2011059326A3 (en) | Hydrogels based on polymers of dextran tyramine and tyramine conjugates of natural polymers | |
MX341475B (es) | Composiciones de copolimero hibrido para aplicaciones de cuidado personal. | |
MX2009008789A (es) | Composiciones de suministro de agentes beneficos. | |
MX2009014279A (es) | Cadenas laterales de ester de fenilo para incrementar la resortividad polimerica. | |
WO2012008722A3 (ko) | 조직 증강용 충전 조성물 | |
NZ600039A (en) | Biocompatible biodegradable fumagillin analog conjugates | |
MX346958B (es) | Composición hemostatica. | |
UA106570C2 (uk) | Суміші полімолочної кислоти й розчинного у воді полімеру | |
MX356185B (es) | Composiciones hemostaticas. | |
MX2010003299A (es) | Oligonucleotidos muy cortos (micromirs). | |
IN2012DN00570A (es) | ||
EP2395048A3 (en) | Polymers compositions including an antioxidant | |
MY156373A (en) | Biodegradable polymer composition | |
WO2012075086A3 (en) | Fabric care composition | |
WO2010033220A3 (en) | Modified therapeutics peptides, methods of their preparation and use | |
MX2013012934A (es) | Nanoparticulas polimericas para el suministro de farmacos. | |
WO2008048775A3 (en) | Gelled dairy compositions and related methods | |
WO2012017288A3 (en) | Supramolecular complexes of polyanionic polymers and spermidine in tissue maintenance and repair | |
MX2012002643A (es) | Diesteres aromaticos con grupos funcionales fluoroeter y derivados de estos. | |
MX2011007288A (es) | Trozos en composicones alimenticias gelatinosas. | |
NZ606723A (en) | Glatiramer acetate molecular weight markers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |